News
News Center
Congratulations to Jiuhua&Huayuan Pharmaceutical Co., Ltd. for being shortlisted in the "Top100 list of Chinese traditional medicine enterprises" for three consecutive years
Release time:
2022-07-13 10:44
Source:
On July 12, 2022, the symbiosis conference of China's pharmaceutical and health industry was held in Huzhou, China. The theme of the conference was "anchoring 'stable' growth". The conference released the "list of top 100 Chinese pharmaceutical industry in 2021". Jiuhua Huayuan Pharmaceutical Co., Ltd. has been listed in the "Top100 list of Chinese traditional medicine enterprises" for three consecutive years.
The "top 100 list of China's pharmaceutical industry in 2021" was selected by the expert committee of the top 100 list of China's pharmaceutical industry organized by michinet, relying on the three terminals and six market terminal pattern database that has been exclusively developed and operated by michinet in China for many years, from the two most important dimensions of innovation driving force and professional promotion for pharmaceutical industry enterprises.
Jiuhua Huayuan Pharmaceutical is committed to becoming a leader in the specialized subdivisions of life sciences. By focusing on and building a core product line, it has formed a leading position in pediatric, respiratory, otolaryngology and other subdivisions, and its performance continued to grow steadily in 2021. Yuye Jinhua antipyretic tablets and misikon granules made from selected Guangxi Ethnic medicinal materials have been successfully listed, providing a new fulcrum for the product layout of Jiuhua Huayuan Pharmaceutical in pediatrics and otolaryngology. In 2021, the planting of the traditional Chinese medicine thymium chinense, the star product of the company, also made a breakthrough, and was recognized as the "top ten Anhui medicine" industrial demonstration base, which laid a solid foundation for the sustainable development of the enterprise. The upstream and downstream industrial integration pattern of Jiuhua Huayuan Pharmaceutical began to take shape.
In the post epidemic era, opportunities and challenges coexist in the future. Stable growth is the key demand of current enterprises, and it is also a response strategy to actively face external challenges. Jiuhua Huayuan Pharmaceutical will adhere to the research and development of new drugs. At the same time, with local offices as the marketing terminals, it will carry out marketing activities by means of academic conferences, project cooperation, academic seminars, etc., and continue to strengthen the promotion, expand market share, and create brand advantages. Anchor the general trend of the industry with brand power, stabilize the strategic layout of the enterprise in the future, and help the sustainable development of productivity! Serve and contribute to the cause of human health.
Related News
2024-09-30
2024-09-30
